Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

January 31, 2009

Conditions

Hematologic Tumors

Interventions

DRUG

Omacetaxine

1.25 mg/m2 subcutaneous twice daily for 14 days

Trial Locations (1)

Mary Crowley Cancer Research Center, Dallas